Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

(Reuters) - Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug Zepbound after it last month ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Both groups followed a reduced-calorie diet and exercise plan. Common side effects ... found in Mounjaro. While Zepbound is FDA-approved for weight loss, Mounjaro is approved for managing type ...

to plan ahead for this year. Lilly's Zepbound and Novo's Wegovy dominate a market for weight-loss treatments that analysts estimate could be a $150 billion market by the early 2030s. Both the ...

When Jeanne began to seriously consider taking Zepbound ... that the loss of muscle mass had depleted his testosterone, Hsu started weight training and boosting the protein in his diet.

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

If you have insurance, but the plan won't cover Zepbound, you'll pay $597 per month ... and have lost at least 5% of your body weight. Requires three months of diet and exercise for weight loss drugs ...